Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.47 |
| ▸ | POLB | P06746 | 4/20 | 0.47 |
| ▸ | HPGD | P15428 | 4/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9293207 | 0.82 | ALDH1A1 (0.49) | NTRK1ALDH1A1POLBHPGDL3MBTL1 | |
| SCHEMBL15128605 | 0.80 | ALDH1A1 (0.48) | NTRK1ALDH1A1POLBHPGDL3MBTL1 | |
| SCHEMBL8448644 | 0.80 | CHRM2 (0.54) | ALDH1A1POLBHPGDL3MBTL1MAPT | |
| SCHEMBL1326250 | 0.79 | ALOX5 (0.53) | NTRK1ALDH1A1POLBHPGDL3MBTL1 | |
| SCHEMBL8440662 | 0.79 | ALDH1A1 (0.60) | ALDH1A1POLBHPGDL3MBTL1MAPT | |
| SCHEMBL11011624 | 0.79 | ALDH1A1 (0.48) | NTRK1ALDH1A1POLBHPGDL3MBTL1 | |
| SCHEMBL26345018 | 0.78 | ALDH1A1 (0.49) | NTRK1ALDH1A1POLBHPGDL3MBTL1 | |
| SCHEMBL3992133 | 0.78 | MAPT (0.60) | NTRK1ALDH1A1POLBHPGDL3MBTL1 | |
| Hydrochloric Acid SCHEMBL5352595 | 0.78 | ALOX5 (0.51) | NTRK1ALDH1A1POLBHPGDL3MBTL1 | |
| SCHEMBL8446606 | 0.78 | POLB (0.59) | ALDH1A1POLBHPGDL3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3541802-B1 | ALKYL SUBSTITUTED TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC (US) | 2025-01-01 | — | — | EP | disclosed |
| US-11191762-B2 | Alkyl substituted triazole compounds as agonists of the APJ Receptor | AMGEN INC. (US) | 2021-12-07 | — | — | US | disclosed |
| US-20190290647-A1 | ALKYL SUBSTITUTED TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC. (US) | 2019-09-26 | — | — | US | disclosed |
| US-7638565-B2 | Polyacetal resin composition | POLYPLASTICS CO., LTD. (JP) | 2009-12-29 | — | — | US | disclosed |
| US-20070054998-A1 | Polyacetal resin composition | POLYPLASTICS CO., LTD. (JP) | 2007-03-08 | — | — | US | disclosed |
| EP-1686156-A1 | POLYACETAL RESIN COMPOSITION | Polyplastics Co., Ltd. (JP) | 2006-08-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11191762-B2 | Alkyl substituted triazole compounds as agonists of the APJ Receptor | AGTR1, AGTR2, APLNR | NTRK1 864/4885ALDH1A1 2364/4885POLB 4064/4885 |
| US-20190290647-A1 | ALKYL SUBSTITUTED TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AGTR1, AGTR2, APLNR | NTRK1 864/4885ALDH1A1 2364/4885POLB 4064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.